Corporate Acquisitions

Eli Lilly has surpassed $20 billion in acquisitions in 2026 alone — a company record — spanning Kelonia Therapeutics ($7B), Centessa Pharmaceuticals ($7.8B), and three vaccine developers ($3.8B). The buying spree reflects a strategic calculation: AI-accelerated drug discovery is compressing pre-clinical timelines, raising the value of early-stage biotech assets. The question is whether external acquisition now outperforms internal R&D as a pipeline-building strategy.

Corporate buyers announced four significant acquisitions spanning restaurant brands, drone technology, petroleum assets, and integrated energy. Smithfield Foods acquired Nathan's Famous, ZenaTech completed 18 firm purchases, Evolution Petroleum bought undisclosed assets, and Chevron finalized its Hess Corporation deal. The 73% confidence trend indicates companies are prioritizing strategic expansion despite market uncertainty.